

dabigatran (PRADAXA)

Diagnoses Considered for Coverage:

- Prevention of stroke and blood clots in patients with atrial fibrillation
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)
- Prevent recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE)
- Prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) following recent hip replacement surgery

Coverage Criteria:

For atrial fibrillation:

- Inadequate response or intolerable side effect with either Eliquis (apixaban) or Xarelto (rivaroxaban) OR contraindication to both drugs, **and**
- Dose does not exceed 300 mg per day.

For treatment or prevention of deep vein thrombosis (DVT) or pulmonary embolism (PE):

- Inadequate response or intolerable side effect with either Eliquis (apixaban) or Xarelto (rivaroxaban) OR contraindication to both drugs, **and**
- Dose does not exceed 300 mg per day.

For prevention of deep vein thrombosis (DVT) or pulmonary embolism (PE) after hip surgery:

- Inadequate response or intolerable side effect with either Eliquis (apixaban) or Xarelto (rivaroxaban) OR contraindication to both drugs, **and**
- Dose does not exceed 110 mg on first day, then 220 mg once a day for 28 to 35 days

Coverage Duration:

- Atrial fibrillation: one year
- Prevention of DVT or PE: one year
- Treatment of DVT or PE: 6 months
- After hip surgery: up to 35 days

Effective Date: 5/31/2023